BioWorld

Jan. 4, 2007

Cytokinetics Forms $725M Heart Disease Alliance With Amgen

Providing leverage for a small-molecule program targeted at heart failure, Cytokinetics Inc. is collaborating with Amgen Inc. in a deal potentially worth $725 million. (BioWorld Today) Read More

Genentech Paying Exelixis $40M In MEK Inhibitor Deal

Cloned Cows Safe, Knockouts Healthy, But Not In Supermarket

FivePrime Signs Discovery Deal With Centocor; $15M Up Front

VaxGen Future Unclear With Additional $51M Celltrion Sale

FDA Signs Off On Poniard's Phase III Picoplatin Protocol

Other News To Note

Clinic Roundup

Today's news in brief

BioWorld

BioWorld briefs for June 17, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for June 16, 2026

For clonal hematopoiesis, epigenetics can be in driver’s seat

BioWorld Science

Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...

Illustration of amyloid plaques in Alzheimer's disease

Elixiron’s enrupatinib shows upbeat interim phase II AD results

BioWorld

Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...

Gene replacement rescues autism-related phenotypes in mice

BioWorld Science

Autism spectrum disorder (ASD), developmental epileptic encephalopathies and other neurodevelopmental disorders are driven by the disruption of genes regulating...